KindlyMD (NAKA) Financials

$7.00 +0.38 (+5.68%)

As of 02:19 PM Eastern

Annual Income Statements for KindlyMD

This table shows KindlyMD's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-1.62	-3.62	-52
Consolidated Net Income / (Loss)	-1.62	-3.62	-52
Net Income / (Loss) Continuing Operations	-1.62	-3.62	-52
Total Pre-Tax Income	-1.62	-3.62	-52
Total Operating Income	-1.62	-3.35	-197
Total Gross Profit	3.77	2.72	1.82
Total Revenue	3.77	2.72	1.82
Operating Revenue	3.77	2.72	1.82
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	5.39	6.07	199
Selling, General & Admin Expense	1.36	1.91	12
Depreciation Expense	0.11	0.14	0.08
Other Operating Expenses / (Income)	3.92	4.02	187
Total Other Income / (Expense), net	0.00	-0.27	145
Interest Expense	0.06	0.43	22
Other Income / (Expense), net	0.06	0.16	167
Income Tax Expense	0.00	0.00	0.00
Basic Earnings per Share	($0.36)	($0.67)	($0.26)
Weighted Average Basic Shares Outstanding	4.50M	5.39M	200.20M
Diluted Earnings per Share	($0.36)	($0.67)	($0.26)
Weighted Average Diluted Shares Outstanding	4.50M	5.39M	200.20M
Weighted Average Basic & Diluted Shares Outstanding	-	6.03M	690.02M

This table shows KindlyMD's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Consolidated Net Income / (Loss)	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Net Income / (Loss) Continuing Operations	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Total Pre-Tax Income	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Total Operating Income	-0.51	-0.30	-0.24	-1.04	-1.05	-1.02	-1.04	-2.39	-10	-183	-126
Total Gross Profit	0.87	0.76	0.83	0.64	0.65	0.60	0.58	0.41	0.39	0.44	2.68
Total Revenue	0.87	0.76	0.83	0.64	0.65	0.60	0.58	0.41	0.39	0.44	2.68
Operating Revenue	0.87	0.76	0.83	0.64	0.65	0.60	0.58	0.41	0.39	0.44	2.68
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	1.38	1.06	1.07	1.68	1.70	1.63	1.62	2.80	11	184	129
Selling, General & Admin Expense	0.34	0.27	0.29	0.44	0.53	0.65	0.59	1.12	4.98	5.07	9.78
Depreciation Expense	0.03	0.03	0.02	0.03	0.03	0.06	0.02	0.01	0.01	0.04	1.12
Other Operating Expenses / (Income)	1.02	0.76	0.72	0.86	1.15	1.30	1.01	1.66	5.80	179	118
Total Other Income / (Expense), net	-0.00	-0.02	-0.05	-0.28	0.04	0.02	0.00	-0.02	-76	221	-113
Interest Expense	0.01	0.04	0.06	0.36	0.01	0.01	0.01	0.00	14	7.32	4.22
Other Income / (Expense), net	0.01	0.01	0.01	0.07	0.05	0.03	0.01	-0.02	-61	228	-108
Income Tax Expense	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	($0.11)	($0.08)	($0.06)	($0.26)	($0.17)	($0.18)	($0.17)	($0.35)	($0.42)	$0.68	($0.38)
Weighted Average Basic Shares Outstanding	4.52M	4.50M	4.62M	5.01M	5.94M	5.39M	6.03M	6.82M	203.09M	200.20M	636.47M
Diluted Earnings per Share	($0.11)	($0.08)	($0.06)	($0.26)	($0.17)	($0.18)	($0.17)	($0.35)	($0.42)	$0.68	($0.38)
Weighted Average Diluted Shares Outstanding	4.52M	4.50M	4.62M	5.01M	5.94M	5.39M	6.03M	6.82M	203.09M	200.20M	636.47M
Weighted Average Basic & Diluted Shares Outstanding	-	0.00	5.94M	5.95M	5.98M	6.03M	6.02M	7.61M	439.85M	690.02M	696.09M

This table details how cash moves in and out of KindlyMD's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	0.34	1.75	20
Net Cash From Operating Activities	-0.45	-3.07	-24
Net Cash From Continuing Operating Activities	-0.45	-3.07	-24
Net Income / (Loss) Continuing Operations	-1.62	-3.62	-52
Consolidated Net Income / (Loss)	-1.62	-3.62	-52
Depreciation Expense	0.11	0.14	0.08
Amortization Expense	0.12	0.46	2.98
Non-Cash Adjustments To Reconcile Net Income	0.75	0.24	30
Changes in Operating Assets and Liabilities, net	0.19	-0.29	-4.06
Net Cash From Investing Activities	-0.01	-0.40	-680
Net Cash From Continuing Investing Activities	-0.01	-0.40	-680
Purchase of Property, Plant & Equipment	-0.01	-0.40	-0.23
Acquisitions	-	-	0.19
Purchase of Investments	-	0.00	-30
Sale and/or Maturity of Investments	-	0.00	5.05
Other Investing Activities, net	-	0.00	-655
Net Cash From Financing Activities	0.80	5.22	724
Net Cash From Continuing Financing Activities	0.80	5.22	724
Repayment of Debt	-0.06	-0.66	-204
Repurchase of Common Equity	0.00	-0.02	-0.32
Issuance of Debt	0.86	0.05	192
Issuance of Common Equity	0.00	5.86	524
Other Financing Activities, net	0.00	-0.00	212
Cash Interest Paid	0.03	0.02	0.00
Cash Income Taxes Paid	0.00	0.00	0.00

This table details how cash moves in and out of KindlyMD's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.04	0.37	-0.24	4.45	-1.10	-1.37	-1.13	4.88	18	-1.60	13
Net Cash From Operating Activities	0.03	-0.21	-0.21	-0.91	-1.05	-0.90	-0.87	-1.91	-13	-7.57	-23
Net Cash From Continuing Operating Activities	0.03	-0.21	-0.21	-0.91	-1.05	-0.90	-0.87	-1.91	-13	-7.57	-23
Net Income / (Loss) Continuing Operations	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Consolidated Net Income / (Loss)	-0.52	-0.32	-0.28	-1.32	-1.01	-1.00	-1.04	-2.41	-86	37	-239
Depreciation Expense	0.03	0.03	0.02	0.03	0.03	0.06	0.02	0.01	0.01	0.04	1.12
Non-Cash Adjustments To Reconcile Net Income	0.33	0.08	-0.02	0.01	0.12	0.13	0.08	0.72	76	-47	221
Changes in Operating Assets and Liabilities, net	0.20	-0.06	-0.01	0.03	-0.21	-0.11	0.08	-0.27	-4.19	0.30	-6.24
Net Cash From Investing Activities	-	-	-0.01	-	-0.00	-0.39	-0.17	-2.35	-684	6.28	37
Net Cash From Continuing Investing Activities	-	-	-0.01	-	-0.00	-0.39	-0.17	-2.35	-684	6.28	37
Purchase of Property, Plant & Equipment	-	-	-0.01	-	-0.00	-0.39	-0.17	-0.06	-0.00	-0.00	0.00
Divestitures	-	-	-	-	-	-	0.00	-	-	-	8.73
Sale and/or Maturity of Investments	-	-	-	-	-	-	0.00	-	-	-	11
Other Investing Activities, net	-	-	-	-	-	-	0.00	-	-639	-14	17
Net Cash From Financing Activities	0.01	0.58	-0.01	5.37	-0.05	-0.08	-0.10	9.14	715	-0.31	-0.56
Net Cash From Continuing Financing Activities	0.01	0.58	-0.01	5.37	-0.05	-0.08	-0.10	9.14	715	-0.31	-0.56
Repayment of Debt	-0.01	-0.03	-0.06	-0.49	-0.05	-0.06	-0.08	-0.07	-204	-	0.00
Repurchase of Common Equity	-	-	0.00	-	-	-	-0.01	-	-	-	-0.56
Other Financing Activities, net	-	-	0.00	-	-	-0.00	-0.00	9.22	203	-	0.00
Cash Interest Paid	0.02	0.02	0.00	0.02	0.00	0.00	0.00	0.00	-0.00	-	0.00
Cash Income Taxes Paid	-	-	0.00	-	-	-	0.00	-	-	-	0.00

This table presents KindlyMD's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Total Assets	1.10	3.68	731
Total Current Assets	0.62	2.51	224
Cash & Equivalents	0.53	2.27	23
Prepaid Expenses	0.00	0.23	2.17
Other Current Assets	-	0.00	199
Plant, Property, & Equipment, net	0.24	0.00	0.00
Total Noncurrent Assets	0.25	1.17	507
Long-Term Investments	-	0.00	36
Goodwill	-	-	0.00
Intangible Assets	0.00	0.00	3.01
Other Noncurrent Operating Assets	0.25	1.17	468
Total Liabilities & Shareholders' Equity	1.10	3.68	731
Total Liabilities	1.21	1.11	216
Total Current Liabilities	0.81	0.61	216
Short-Term Debt	0.15	0.14	210
Accounts Payable	0.33	0.32	5.86
Current Deferred Revenue	-	-	0.00
Other Current Liabilities	0.33	0.14	0.57
Total Noncurrent Liabilities	0.39	0.50	0.37
Noncurrent Deferred Revenue	-	-	0.00
Other Noncurrent Operating Liabilities	0.16	0.50	0.37
Commitments & Contingencies	-	0.00	0.00
Total Equity & Noncontrolling Interests	-0.11	2.57	514
Total Preferred & Common Equity	-0.11	2.57	514
Preferred Stock	0.00	0.00	0.00
Total Common Equity	-0.11	2.57	514
Common Stock	4.05	10	575
Retained Earnings	-4.16	-7.78	-60
Treasury Stock	0.00	-0.02	-0.75
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00

This table presents KindlyMD's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	0.80	5.46	4.32	2.56	9.89	692	621
Total Current Assets	0.36	5.05	3.94	1.29	6.37	27	63
Cash & Equivalents	0.29	4.74	3.64	1.14	6.02	24	35
Prepaid Expenses	0.01	0.31	0.25	0.14	0.34	2.87	14
Other Current Assets	-	-	-	-	-	-	14
Plant, Property, & Equipment, net	0.22	0.21	0.18	0.11	0.08	0.00	0.00
Total Noncurrent Assets	0.22	0.20	0.20	1.16	3.43	665	557
Long-Term Investments	-	-	-	-	-	46	17
Goodwill	-	-	-	-	-	-	94
Intangible Assets	-	-	-	0.56	0.62	3.01	101
Other Noncurrent Operating Assets	0.22	0.20	0.20	0.60	0.56	616	0.19
Other Noncurrent Nonoperating Assets	-	-	-	-	2.25	-	346
Total Liabilities & Shareholders' Equity	0.80	5.46	4.32	2.56	9.89	692	621
Total Liabilities	1.18	1.08	0.84	1.03	0.92	215	254
Total Current Liabilities	0.86	0.94	0.73	0.56	0.49	214	252
Short-Term Debt	0.20	0.23	0.19	0.06	0.00	203	210
Accounts Payable	0.30	0.63	0.43	0.37	0.36	5.85	13
Current Deferred Revenue	-	-	-	-	-	-	23
Other Current Liabilities	0.36	0.08	0.10	0.13	0.13	5.60	5.75
Total Noncurrent Liabilities	0.32	0.13	0.11	0.47	0.43	0.40	1.99
Noncurrent Deferred Revenue	-	-	-	-	-	-	1.62
Other Noncurrent Operating Liabilities	0.14	0.13	0.11	0.47	0.43	0.40	0.37
Commitments & Contingencies	-	-	-	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	-0.38	4.38	3.48	1.53	8.97	478	367
Total Preferred & Common Equity	-0.38	4.38	3.48	1.53	8.97	478	367
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-0.38	4.38	3.48	1.53	8.97	478	367
Common Stock	4.06	10	10	10	20	575	666
Retained Earnings	-4.44	-5.76	-6.77	-8.81	-11	-97	-299
Treasury Stock	-	-	-	-0.03	0.00	0.00	0.00
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-	-	-0.13

This table displays calculated financial ratios and metrics derived from KindlyMD's official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	5,977,476.00	439,850,889.00
DEI Adjusted Shares Outstanding	0.00	5,977,476.00	439,850,889.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-0.61	-0.12
Growth Metrics	-	-	-
Revenue Growth	0.00%	-27.83%	-33.04%
EBITDA Growth	0.00%	-93.60%	-956.88%
EBIT Growth	0.00%	-103.98%	-855.82%
NOPAT Growth	0.00%	-106.56%	-5,790.43%
Net Income Growth	0.00%	-123.66%	-1,343.73%
EPS Growth	0.00%	-86.11%	61.19%
Operating Cash Flow Growth	0.00%	-583.86%	-664.88%
Free Cash Flow Firm Growth	0.00%	0.00%	-26,376.71%
Invested Capital Growth	0.00%	269.17%	153,262.15%
Revenue Q/Q Growth	0.00%	-5.41%	-8.03%
EBITDA Q/Q Growth	0.00%	-38.40%	63.56%
EBIT Q/Q Growth	0.00%	-28.35%	59.95%
NOPAT Q/Q Growth	0.00%	-27.43%	-1,226.52%
Net Income Q/Q Growth	0.00%	-23.01%	42.28%
EPS Q/Q Growth	0.00%	-17.54%	76.79%
Operating Cash Flow Q/Q Growth	0.00%	-29.10%	-39.57%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-29.36%
Invested Capital Q/Q Growth	0.00%	1,046.96%	9.03%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-35.51%	-95.24%	-1,503.20%
Operating Margin	-42.99%	-123.05%	-10,824.01%
EBIT Margin	-41.44%	-117.11%	-1,671.63%
Profit (Net Income) Margin	-42.92%	-133.01%	-2,867.65%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	103.58%	113.57%	171.55%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,640.61%	-41.44%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,528.90%	73.57%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,346.48%	21.23%
Return on Equity (ROE)	1,491.96%	-294.13%	-20.21%
Cash Return on Invested Capital (CROIC)	0.00%	-698.96%	-241.18%
Operating Return on Assets (OROA)	-142.07%	-133.35%	-8.29%
Return on Assets (ROA)	-147.15%	-151.45%	-14.23%
Return on Common Equity (ROCE)	1,491.96%	-294.13%	-20.21%
Return on Equity Simple (ROE_SIMPLE)	1,491.96%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.13	-2.34	-138
NOPAT Margin	-30.09%	-86.14%	-7,576.80%
Net Nonoperating Expense Percent (NNEP)	-326.31%	-111.71%	-115.01%
Return On Investment Capital (ROIC_SIMPLE)	-421.66%	-86.53%	-19.07%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	35.98%	70.12%	645.82%
R&D to Revenue	0.07%	0.00%	0.00%
Operating Expenses to Revenue	142.99%	223.05%	10,924.01%
Earnings before Interest and Taxes (EBIT)	-1.56	-3.19	-30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.34	-2.59	-27
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	2.89	0.30
Price to Tangible Book Value (P/TBV)	0.00	2.89	0.30
Price to Revenue (P/Rev)	1.86	2.73	84.79
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	12.16	0.46
Enterprise Value to Revenue (EV/Rev)	1.82	1.94	167.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	-3.48	0.05	0.41
Long-Term Debt to Equity	-2.11	0.00	0.00
Financial Leverage	1.37	-0.93	0.29
Leverage Ratio	-10.14	1.94	1.42
Compound Leverage Factor	-10.50	2.21	2.44
Debt to Total Capital	140.31%	5.14%	28.95%
Short-Term Debt to Total Capital	55.22%	5.14%	28.95%
Long-Term Debt to Total Capital	85.09%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	-40.31%	94.86%	71.05%
Debt to EBITDA	-0.28	-0.05	-7.65
Net Debt to EBITDA	0.11	0.82	-5.53
Long-Term Debt to EBITDA	-0.17	0.00	0.00
Debt to NOPAT	-0.33	-0.06	-1.52
Net Debt to NOPAT	0.13	0.91	-1.10
Long-Term Debt to NOPAT	-0.20	0.00	0.00
Altman Z-Score	-3.29	-0.45	0.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	0.76	4.13	1.04
Quick Ratio	0.68	3.75	0.10
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-3.03	-803
Operating Cash Flow to CapEx	-3,117.12%	-765.35%	-10,031.23%
Free Cash Flow to Firm to Interest Expense	0.00	-7.02	-36.87
Operating Cash Flow to Interest Expense	-8.05	-7.11	-1.08
Operating Cash Flow Less CapEx to Interest Expense	-8.31	-8.04	-1.09
Efficiency Ratios	-	-	-
Asset Turnover	3.43	1.14	0.01
Accounts Receivable Turnover	134.59	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	16.02	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	2.71	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	2.71	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-0.26	0.43	666
Invested Capital Turnover	-14.69	30.66	0.01
Increase / (Decrease) in Invested Capital	0.00	0.69	665
Enterprise Value (EV)	6.85	5.28	306
Market Capitalization	7.00	7.41	154
Book Value per Share	($0.02)	$0.43	$1.17
Tangible Book Value per Share	($0.02)	$0.43	$1.16
Total Capital	0.27	2.71	724
Total Debt	0.38	0.14	210
Total Long-Term Debt	0.23	0.00	0.00
Net Debt	-0.15	-2.13	151
Capital Expenditures (CapEx)	0.01	0.40	0.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.57	-0.23	195
Debt-free Net Working Capital (DFNWC)	-0.05	2.04	217
Net Working Capital (NWC)	-0.20	1.90	7.83
Net Nonoperating Expense (NNE)	0.48	1.27	-86
Net Nonoperating Obligations (NNO)	-0.15	-2.13	151
Total Depreciation and Amortization (D&A)	0.22	0.59	3.07
Debt-free, Cash-free Net Working Capital to Revenue	-15.24%	-8.63%	10,695.95%
Debt-free Net Working Capital to Revenue	-1.30%	74.96%	11,935.88%
Net Working Capital to Revenue	-5.24%	69.84%	430.02%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.67)	($0.26)
Adjusted Weighted Average Basic Shares Outstanding	0.00	5.39M	200.20M
Adjusted Diluted Earnings per Share	$0.00	($0.67)	($0.26)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	5.39M	200.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	6.03M	690.02M
Normalized Net Operating Profit after Tax (NOPAT)	-1.13	-2.34	-138
Normalized NOPAT Margin	-30.09%	-86.14%	-7,576.80%
Pre Tax Income Margin	-42.92%	-133.01%	-2,867.65%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-27.96	-7.37	-1.40
NOPAT to Interest Expense	-20.31	-5.42	-6.34
EBIT Less CapEx to Interest Expense	-28.22	-8.30	-1.41
NOPAT Less CapEx to Interest Expense	-20.57	-6.35	-6.35
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.61%	-0.61%

This table displays calculated financial ratios and metrics derived from KindlyMD's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	0.00	0.00	0.00	5,939,516.00	5,947,169.00	5,977,476.00	6,029,648.00	6,022,148.00	7,606,339.00	439,850,889.00	690,018,254.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	5,939,516.00	5,947,169.00	5,977,476.00	6,029,648.00	6,022,148.00	7,606,339.00	439,850,889.00	690,018,254.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-0.22	-0.17	-0.17	-0.17	-0.40	-11.31	0.08	-0.35
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	-28.55%	-34.76%	-25.47%	-20.48%	-30.04%	-36.07%	-40.08%	-26.32%	361.72%
EBITDA Growth	0.00%	0.00%	-3.49%	-12.87%	-95.08%	-362.57%	-694.86%	-292.32%	-7,399.52%	5,207.89%	-22,921.79%
EBIT Growth	0.00%	0.00%	-24.37%	-63.60%	-99.86%	-242.76%	-358.49%	-150.45%	-7,026.15%	4,587.26%	-22,628.29%
NOPAT Growth	0.00%	0.00%	-15.56%	-72.49%	-105.20%	-238.48%	-339.43%	-130.57%	-891.17%	-25,506.24%	-12,008.45%
Net Income Growth	0.00%	0.00%	-56.00%	-121.27%	-96.87%	-208.23%	-267.66%	-82.91%	-8,383.56%	3,820.21%	-22,903.47%
EPS Growth	0.00%	0.00%	-50.00%	-100.00%	-54.55%	-125.00%	-183.33%	-34.62%	-147.06%	477.78%	-123.53%
Operating Cash Flow Growth	0.00%	0.00%	-227.73%	-106.65%	-3,160.44%	-332.01%	-305.27%	-109.21%	-1,159.60%	-739.41%	-2,591.91%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,229.92%	-319.84%	-79,837.50%	-60,227.34%	-17,894.97%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	269.17%	253.59%	627.21%	1,613,278.46%	153,262.15%	39,116.07%
Revenue Q/Q Growth	-11.26%	-12.63%	9.16%	-22.92%	1.38%	-6.79%	-3.96%	-29.52%	-4.97%	14.61%	501.90%
EBITDA Q/Q Growth	8.85%	59.10%	35.65%	-370.51%	-57.54%	3.02%	-10.57%	-148.21%	-2,911.50%	166.05%	-598.36%
EBIT Q/Q Growth	14.56%	42.33%	22.34%	-327.53%	-4.38%	1.10%	-3.88%	-133.61%	-2,870.03%	162.28%	-626.18%
NOPAT Q/Q Growth	14.92%	40.94%	21.51%	-337.40%	-1.22%	2.59%	-1.89%	-129.57%	-335.11%	-2,416.53%	51.82%
Net Income Q/Q Growth	13.63%	36.93%	13.11%	-367.42%	23.15%	1.25%	-3.64%	-132.54%	-3,464.35%	143.31%	-740.86%
EPS Q/Q Growth	15.38%	27.27%	25.00%	-333.33%	34.62%	-5.88%	5.56%	-105.88%	-20.00%	261.90%	-155.88%
Operating Cash Flow Q/Q Growth	107.73%	-710.93%	-2.28%	-328.01%	-14.43%	13.76%	4.05%	-120.93%	-588.97%	42.53%	-207.70%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-553.12%	-29.91%	-82.00%	-5.47%	-68.38%	-24,635.32%	-37.35%	68.54%
Invested Capital Q/Q Growth	0.00%	0.00%	-15.88%	55.85%	128.83%	1,046.96%	5.20%	51.55%	88,127.21%	9.03%	-73.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-55.76%	-26.10%	-15.39%	-93.92%	-145.96%	-151.86%	-174.83%	-576.42%	-18,267.49%	10,528.00%	-8,716.99%
Operating Margin	-58.85%	-39.78%	-28.60%	-162.30%	-162.04%	-169.34%	-179.66%	-585.39%	-2,680.39%	-41,198.16%	-4,711.35%
EBIT Margin	-57.82%	-38.16%	-27.15%	-150.58%	-155.05%	-164.50%	-177.93%	-589.95%	-18,438.86%	10,019.11%	-8,758.63%
Profit (Net Income) Margin	-59.26%	-42.78%	-34.06%	-206.50%	-156.54%	-165.85%	-178.97%	-590.85%	-22,162.24%	8,374.17%	-8,916.21%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	102.50%	112.11%	125.43%	137.13%	100.96%	100.82%	100.58%	100.15%	120.19%	83.58%	101.80%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	-17,240.48%	-3,634.01%	-3,901.38%	-3,274.28%	-12.17%	-225.34%	-144.02%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	-17,224.27%	-3,608.98%	-3,838.83%	-3,262.70%	-133.86%	70.43%	15.10%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	17,037.22%	3,348.65%	3,305.21%	3,125.66%	-36.02%	20.32%	-7.75%
Return on Equity (ROE)	0.00%	1,491.96%	448.63%	-55.75%	-203.26%	-285.36%	-596.17%	-148.62%	-48.19%	-205.02%	-151.77%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-698.96%	-801.66%	-675.99%	-203.38%	-241.18%	-450.34%
Operating Return on Assets (OROA)	0.00%	-130.84%	-116.76%	-85.46%	-103.10%	-187.32%	-261.46%	-172.21%	-104.81%	49.70%	-110.14%
Return on Assets (ROA)	0.00%	-146.69%	-146.45%	-117.19%	-104.09%	-188.84%	-262.98%	-172.47%	-125.98%	41.54%	-112.13%
Return on Common Equity (ROCE)	0.00%	1,491.96%	448.63%	-55.75%	-203.26%	-285.36%	-596.17%	-148.62%	-48.19%	-205.02%	-151.77%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	448.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.36	-0.21	-0.17	-0.73	-0.73	-0.72	-0.73	-1.67	-7.28	-183	-88
NOPAT Margin	-41.20%	-27.85%	-20.02%	-113.61%	-113.43%	-118.54%	-125.76%	-409.78%	-1,876.27%	-41,198.16%	-3,297.95%
Net Nonoperating Expense Percent (NNEP)	0.00%	-76.59%	270.97%	-26.31%	-16.21%	-25.03%	-62.56%	-11.57%	121.69%	-295.77%	-159.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-78.63%	1,681.41%	-15.75%	-19.97%	-26.44%	-45.67%	-18.67%	-1.07%	-25.32%	-15.31%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	39.06%	35.92%	35.00%	69.47%	81.15%	107.17%	102.24%	274.52%	1,283.52%	1,138.55%	365.35%
R&D to Revenue	0.00%	0.00%	4.27%	53.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	158.85%	139.78%	128.60%	262.30%	262.04%	269.34%	279.66%	685.39%	2,780.39%	41,298.16%	4,811.35%
Earnings before Interest and Taxes (EBIT)	-0.50	-0.29	-0.23	-0.96	-1.00	-0.99	-1.03	-2.41	-72	45	-235
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.48	-0.20	-0.13	-0.60	-0.95	-0.92	-1.01	-2.35	-71	47	-233
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	3.73	1.79	2.89	6.35	9.30	0.02	0.30	0.42
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	3.73	1.79	2.89	10.04	9.99	0.02	0.30	0.88
Price to Revenue (P/Rev)	0.00	1.86	2.04	5.27	2.17	2.73	3.93	37.22	4.11	84.79	38.89
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	73.96	12.16	18.91	111.80	0.23	0.46	1.73
Enterprise Value to Revenue (EV/Rev)	0.00	1.82	2.06	3.82	0.97	1.94	3.49	34.53	71.21	167.85	79.09
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	-3.48	-0.97	0.05	0.06	0.05	0.04	0.00	0.43	0.41	0.57
Long-Term Debt to Equity	0.00	-2.11	-0.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	1.37	-0.22	-1.03	-0.99	-0.93	-0.86	-0.96	0.27	0.29	-0.51
Leverage Ratio	0.00	-10.14	-2.09	1.25	1.24	1.94	2.93	1.15	1.45	1.42	1.69
Compound Leverage Factor	0.00	-11.37	-2.62	1.71	1.25	1.96	2.95	1.15	1.74	1.19	1.72
Debt to Total Capital	0.00%	140.31%	-3,780.90%	4.95%	5.34%	5.14%	4.26%	0.00%	29.83%	28.95%	36.36%
Short-Term Debt to Total Capital	0.00%	55.22%	-1,985.05%	4.95%	5.12%	5.14%	3.82%	0.00%	29.83%	28.95%	36.36%
Long-Term Debt to Total Capital	0.00%	85.09%	-1,795.85%	0.00%	0.22%	0.00%	0.44%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-40.31%	3,880.90%	95.05%	94.66%	94.86%	95.74%	100.00%	70.17%	71.05%	63.64%
Debt to EBITDA	0.00	-0.28	-0.28	-0.16	-0.11	-0.05	-0.02	0.00	-2.70	-7.65	-0.80
Net Debt to EBITDA	0.00	0.11	-0.06	3.20	1.84	0.82	0.28	0.00	-1.77	-5.53	-0.60
Long-Term Debt to EBITDA	0.00	-0.17	-0.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.33	-0.32	-0.16	-0.11	-0.06	-0.02	0.00	-19.52	-1.52	-0.93
Net Debt to NOPAT	0.00	0.13	-0.07	3.09	1.87	0.91	0.37	0.00	-12.77	-1.10	-0.70
Long-Term Debt to NOPAT	0.00	-0.20	-0.15	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.52	-1.61	8.52	3.06	1.52	0.80	52.72	-0.84	0.53	-1.92
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.76	0.41	5.36	5.43	4.13	2.30	12.99	0.13	1.04	0.25
Quick Ratio	0.00	0.68	0.34	5.03	5.08	3.75	2.05	12.30	0.11	0.10	0.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.13	-0.59	-0.77	-1.41	-1.48	-2.50	-618	-848	-267
Operating Cash Flow to CapEx	0.00%	0.00%	-1,908.77%	0.00%	-49,567.80%	-232.15%	-500.00%	-3,290.95%	-460,568.94%	-756,753,100.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	2.29	-1.66	-80.00	-173.62	-247.20	-680.80	-42.73	-115.92	-63.25
Operating Cash Flow to Interest Expense	2.72	-5.95	-3.73	-2.56	-108.23	-111.30	-144.17	-521.05	-0.91	-1.03	-5.52
Operating Cash Flow Less CapEx to Interest Expense	2.72	-5.95	-3.92	-2.56	-108.45	-159.24	-173.00	-536.89	-0.91	-1.03	-5.52
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	3.43	4.30	0.57	0.67	1.14	1.47	0.29	0.01	0.01	0.01
Accounts Receivable Turnover	0.00	134.59	455.03	597.61	63.44	0.00	233.45	354.03	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	16.02	15.51	14.97	15.68	0.00	15.12	15.40	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	2.71	0.80	0.61	5.75	0.00	1.56	1.03	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	2.71	0.80	0.61	5.75	0.00	1.56	1.03	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-0.26	-0.30	-0.13	0.04	0.43	0.46	0.69	610	666	179
Invested Capital Turnover	0.00	-14.69	-23.13	-47.19	151.99	30.66	31.02	7.99	0.01	0.01	0.04
Increase / (Decrease) in Invested Capital	0.00	0.00	-0.30	-0.13	0.04	0.69	0.75	0.82	610	665	179
Enterprise Value (EV)	0.00	6.85	7.09	12	2.80	5.28	8.64	77	141	306	310
Market Capitalization	7.00	7.00	7.00	16	6.24	7.41	9.71	83	8.14	154	152
Book Value per Share	$0.00	($0.02)	($0.08)	$0.74	$0.59	$0.43	$0.25	$1.49	$62.78	$1.17	$0.53
Tangible Book Value per Share	$0.00	($0.02)	($0.08)	$0.74	$0.59	$0.43	$0.16	$1.39	$62.39	$1.16	$0.25
Total Capital	0.00	0.27	-0.01	4.61	3.68	2.71	1.60	8.97	681	724	577
Total Debt	0.00	0.38	0.37	0.23	0.20	0.14	0.07	0.00	203	210	210
Total Long-Term Debt	0.00	0.23	0.18	0.00	0.01	0.00	0.01	0.00	0.00	0.00	0.00
Net Debt	0.00	-0.15	0.09	-4.51	-3.45	-2.13	-1.07	-6.02	133	151	158
Capital Expenditures (CapEx)	0.00	0.00	0.01	0.00	0.00	0.39	0.17	0.06	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-0.57	-0.60	-0.40	-0.24	-0.23	-0.35	-0.14	-8.58	195	-14
Debt-free Net Working Capital (DFNWC)	0.00	-0.05	-0.31	4.34	3.40	2.04	0.79	5.88	16	217	21
Net Working Capital (NWC)	0.00	-0.20	-0.51	4.11	3.22	1.90	0.73	5.88	-187	7.83	-188
Net Nonoperating Expense (NNE)	0.16	0.11	0.12	0.59	0.28	0.29	0.31	0.74	79	-221	150
Net Nonoperating Obligations (NNO)	0.00	-0.15	0.09	-4.51	-3.45	-2.13	-1.07	-8.27	133	151	-188
Total Depreciation and Amortization (D&A)	0.02	0.09	0.10	0.36	0.06	0.08	0.02	0.06	0.67	2.26	1.12
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-15.24%	-17.36%	-12.92%	-8.31%	-8.63%	-14.06%	-6.37%	-433.04%	10,695.95%	-353.12%
Debt-free Net Working Capital to Revenue	0.00%	-1.30%	-9.00%	140.14%	118.39%	74.96%	32.10%	262.59%	788.26%	11,935.88%	547.54%
Net Working Capital to Revenue	0.00%	-5.24%	-14.70%	132.77%	111.83%	69.84%	29.63%	262.59%	-9,463.71%	430.02%	-4,803.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.08)	($0.06)	($0.26)	($0.17)	($0.18)	($0.17)	($0.35)	($0.42)	$0.68	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	0.00	4.50M	4.62M	5.01M	5.94M	5.39M	6.02M	6.82M	203.09M	200.20M	636.47M
Adjusted Diluted Earnings per Share	$0.00	($0.08)	($0.06)	($0.26)	($0.17)	($0.18)	($0.17)	($0.35)	($0.42)	$0.68	($0.38)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	4.50M	4.62M	5.01M	5.94M	5.39M	6.02M	6.82M	203.09M	200.20M	636.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	5.94M	5.95M	5.98M	6.03M	6.02M	7.61M	439.85M	690.02M	696.09M
Normalized Net Operating Profit after Tax (NOPAT)	-0.36	-0.21	-0.17	-0.73	-0.73	-0.72	-0.73	-1.67	-7.28	-128	-88
Normalized NOPAT Margin	-41.20%	-27.85%	-20.02%	-113.61%	-113.43%	-118.54%	-125.76%	-409.78%	-1,876.27%	-28,838.71%	-3,297.95%
Pre Tax Income Margin	-59.26%	-42.78%	-34.06%	-206.50%	-156.54%	-165.85%	-178.97%	-590.85%	-22,162.24%	8,374.17%	-8,916.21%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-40.05	-8.26	-3.93	-2.69	-104.00	-122.64	-172.00	-657.07	-4.95	6.09	-55.58
NOPAT to Interest Expense	-28.54	-6.03	-2.90	-2.03	-76.08	-88.38	-121.57	-456.39	-0.50	-25.05	-20.93
EBIT Less CapEx to Interest Expense	-40.05	-8.26	-4.13	-2.69	-104.21	-170.59	-200.83	-672.90	-4.95	6.09	-55.58
NOPAT Less CapEx to Interest Expense	-28.54	-6.03	-3.10	-2.03	-76.30	-136.32	-150.40	-472.22	-0.50	-25.05	-20.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.61%	-0.74%	-0.58%	0.00%	-0.61%	-0.30%

Financials Breakdown Chart

Key Financial Trends

Kindly MD, Inc. (NASDAQ: KDLY) has shown a dramatic turnaround in revenue and earnings trends over the last four years, but the latest quarter also highlights major balance-sheet and dilution concerns. Q1 2026 was a very different picture from the prior-year quarters: revenue jumped sharply to $2.7 million from $444.9 thousand in Q4 2025, and the company reported a much smaller loss than the large operating losses seen in late 2025. At the same time, KDLY remains highly dependent on non-operating items, has a large debt load, and has relied heavily on equity issuance.

Top takeaways for retail investors:

Q1 2026 revenue rose to $2.68 million, a major improvement from $444.9 thousand in Q4 2025 and above the roughly $388 thousand to $580 thousand range seen in most of 2025 and 2024.
Operating cash flow improved sequentially, with Q1 2026 net cash used in operations narrowing to a $23.3 million outflow versus a $7.6 million outflow in Q4 2025 and much smaller outflows in earlier periods.
The balance sheet ended Q1 2026 with $35.3 million in cash and equivalents, up from $24.2 million at the end of Q3 2025 and $6.0 million at the end of Q2 2025.
Equity increased materially in Q1 2026 to $367.1 million, helped by the company’s larger asset base and financing activity.
Q1 2026 reported a net cash inflow from investing activities of $36.6 million, supported by divestitures, investment sales, and other investing items rather than recurring operating performance.
The company’s share count has been volatile and generally elevated, reflecting meaningful dilution over time and making per-share comparisons harder for investors.
Operating results have been inconsistent quarter to quarter, with KDLY swinging between modest losses and unusually large gains/losses driven by non-operating items.
Q1 2026 still posted a large net loss of $238.8 million, driven by $108.4 million in other expense and a $126.2 million operating loss.
Short-term debt was $209.7 million at the end of Q1 2026, far exceeding cash on hand and representing a major leverage concern.
The company has repeatedly relied on capital raises and debt activity, including a very large common equity issuance in Q3 2025, which suggests ongoing financing dependence.

Revenue trend: KDLY’s revenue history shows volatility, but the latest quarter was a clear step up. Revenue was $829 thousand in Q1 2024, $639 thousand in Q2 2024, $648 thousand in Q3 2024, and $604 thousand in Q4 2024. In 2025, it slipped to $580 thousand in Q1 and $408 thousand in Q2 before dropping to $388 thousand in Q3 and just $445 thousand in Q4. The rebound to $2.68 million in Q1 2026 stands out, although one quarter does not yet establish a durable trend.

Profitability trend: The company has generally remained unprofitable at the operating level. Q1 2026 included $2.68 million of gross profit, but operating expenses were $128.8 million, leading to a $126.2 million operating loss. In 2025, operating losses were also severe, including a $183.3 million loss in Q4 and an $86.0 million net loss in Q3. Earlier periods in 2024 and early 2025 showed much smaller losses, but still no sustained profitability.

Cash flow and balance sheet: Q1 2026 showed a strong cash build from investing activity, but operating cash burn remained significant. Cash increased to $35.3 million, yet short-term debt was $209.7 million and total liabilities were $253.7 million. Total assets were $620.8 million, which means the balance sheet is asset-heavy, but much of that value appears tied to goodwill, intangibles, and noncurrent nonoperating assets rather than liquid resources. That can be supportive on paper, but it does not solve the company’s operating cash-flow problem.

Dilution and financing: KDLY’s history shows heavy reliance on external financing. In Q3 2025, the company issued $523.7 million of common equity and $191.9 million of debt, which is a major signal that management has leaned on capital markets to fund operations and transactions. The weighted average share count also varies dramatically across periods, indicating meaningful dilution for existing shareholders.

Bottom line: Kindly MD’s latest quarter shows better revenue momentum and a stronger cash position, but the company is still carrying substantial debt, posting large losses, and depending on financing and non-operating gains. For retail investors, the key question is whether Q1 2026 marks the start of a real operating turnaround or just another volatile quarter in a highly unsettled financial profile.

05/22/26 12:11 PM ETAI Generated. May Contain Errors.

KindlyMD Financials - Frequently Asked Questions

According to the most recent income statement we have on file, KindlyMD's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

KindlyMD's net income appears to be on an upward trend, with a most recent value of -$52.23 million in 2025, rising from -$1.62 million in 2023. The previous period was -$3.62 million in 2024. See where experts think KindlyMD is headed by visiting KindlyMD's forecast page.

KindlyMD's total operating income in 2025 was -$197.14 million, based on the following breakdown:

Total Gross Profit: $1.82 million
Total Operating Expenses: $198.96 million

Over the last 2 years, KindlyMD's total revenue changed from $3.77 million in 2023 to $1.82 million in 2025, a change of -51.7%.

KindlyMD's total liabilities were at $216.35 million at the end of 2025, a 19,396.7% increase from 2024, and a 17,815.6% increase since 2023.

In the past 2 years, KindlyMD's cash and equivalents has ranged from $525.50 thousand in 2023 to $22.58 million in 2025, and is currently $22.58 million as of their latest financial filing in 2025.

Over the last 2 years, KindlyMD's book value per share changed from -0.02 in 2023 to 1.17 in 2025, a change of -4,951.5%.

Related Companies

Financial statements for NASDAQ:NAKA last updated on 5/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KindlyMD (NAKA) Financials

Financials Breakdown Chart

Key Financial Trends

KindlyMD Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KindlyMD (NAKA) Financials

Annual Income Statements for KindlyMD

Quarterly Income Statements for KindlyMD

Annual Cash Flow Statements for KindlyMD

Quarterly Cash Flow Statements for KindlyMD

Annual Balance Sheets for KindlyMD

Quarterly Balance Sheets for KindlyMD

Annual Metrics And Ratios for KindlyMD

Quarterly Metrics And Ratios for KindlyMD

Financials Breakdown Chart

Key Financial Trends

KindlyMD Financials - Frequently Asked Questions

When does KindlyMD's financial year end?

How has KindlyMD's net income changed over the last 2 years?

What is KindlyMD's operating income?

How has KindlyMD's revenue changed over the last 2 years?

How much debt does KindlyMD have?

How much cash does KindlyMD have?

How has KindlyMD's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools